/AVR
AVR Stock - Anteris Technologies Global Corp.
Healthcare|Medical - DevicesNASDAQ
$4.43-2.73%
$0.12 (-2.73%) • Jan 13
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.55
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+103.4%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.38 – $4.47
TARGET (TP)$9.00
STOP LOSS$4.07
RISK/REWARD1:12.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$8.79
52W Low$2.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.70M | $2.73M | $3.20M | $5.83M | $5.46M |
| Gross Profit | $1.27M | $876,800 | $298,383 | $1.91M | $3.36M |
| Gross Margin | 46.8% | 32.1% | 9.3% | 32.7% | 61.5% |
| Operating Income | $-78,372,000 | $-48,139,988 | $-31,114,275 | $-16,860,576 | $-13,261,734 |
| Net Income | $-76,291,000 | $-46,021,841 | $-30,563,800 | $-17,171,057 | $-11,776,818 |
| Net Margin | -2822.5% | -1682.8% | -954.9% | -294.5% | -215.8% |
| EPS | $-3.77 | $-1.28 | $-0.85 | $-0.48 | $-0.33 |
Company Overview
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 272.8% Upside
Now
$9
Low
$17
Average
$22
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 8th 2025 | Lake Street | Initiation | Buy | $20 |
| January 7th 2025 | TD Cowen | Initiation | Buy | $15 |
| January 7th 2025 | Cantor Fitzgerald | Initiation | Overweight | $9 |
| January 7th 2025 | Barclays | Initiation | Overweight | $22 |
Earnings History & Surprises
AVRBeat Rate
0%
Last 3 quarters
Avg Surprise
-20.8%
EPS vs Estimate
Beats / Misses
0/3
Last 12 quarters
Latest EPS
$-0.62
Q4 2025
EPS Surprise History
Q2 25
No data
Q2 25
-35.6%
$-0.61vs$-0.45
Q3 25
-16.0%
$-0.58vs$-0.50
Q4 25
-10.7%
$-0.62vs$-0.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.56 | $-0.62 | -10.7% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.50 | $-0.58 | -16.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.45 | $-0.61 | -35.6% | ✗ MISS |
Q2 2025 | Apr 29, 2025 | — | $-0.82 | — | — |
Latest News
Anteris Technologies Global Files For Mixed Shelf Of Up To $500M
📈 PositiveBenzinga•Jan 2, 2026, 10:24 PM
Anteris Technologies Declines Renewal Of ADAPT Tissue Supply Agreement With 4C Medical, Contract To End June 2026; Termination Does Not Impact Financial Results
➖ NeutralBenzinga•Dec 1, 2025, 09:47 PM
Anteris Technologies Global To Offer Up To 9.1M Shares Of Common Stock By The Selling Stockholders
➖ NeutralBenzinga•Nov 26, 2025, 09:40 PM
Anteris Highlights 100% Technical Success In Last 50 DurAVR THV Implants And No Valve Related Mortality At 30 Days
📈 PositiveBenzinga•Nov 17, 2025, 11:04 AM
Anteris Technologies Glb Q3 EPS $(0.62) Misses $(0.57) Estimate, Sales $429.000K Beat $400.000K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 11:02 PM
Anteris Receives FDA Approval To Initiate PARADIGM, Global IDE Clinical Trial Designed To Evaluate DurAVR THV In Patients With Severe Calcific Aortic Stenosis And To Support Future PMA Submission
📈 PositiveBenzinga•Nov 3, 2025, 12:24 PM
Anteris Technologies Enrolls First Patients In Global PARADIGM Pivotal Trial Of DurAVR Transcatheter Heart Valve For Severe Aortic Stenosis
📈 PositiveBenzinga•Oct 27, 2025, 09:47 PM
Anteris Technologies To Present One-Year Clinical Outcomes With DurAVR Transcatheter Heart Valve, At TCT 2025
📈 PositiveBenzinga•Oct 27, 2025, 12:47 PM
Anteris Technologies Receives Danish Regulatory Clearance To Launch Global PARADIGM Trial For DurAVR Heart Valve
📈 PositiveBenzinga•Oct 15, 2025, 01:21 PM
Frequently Asked Questions about AVR
What is AVR's current stock price?
Anteris Technologies Global Corp. (AVR) is currently trading at $4.43 per share. The stock has moved -2.73% today.
What is the analyst price target for AVR?
The average analyst price target for AVR is $9.00, based on 1 analyst.
What sector is Anteris Technologies Global Corp. in?
Anteris Technologies Global Corp. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is AVR's market cap?
Anteris Technologies Global Corp. has a market capitalization of $0.15 billion, making it a small-cap company.
Does AVR pay dividends?
No, Anteris Technologies Global Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANIK
Anika Therapeutics, Inc.
$9.57
Mkt Cap: $0.1B
ARAY
Accuray Incorporated
$0.86
Mkt Cap: $0.1B
ATLN
Atlantic International Corp.
$1.82
Mkt Cap: $0.1B
CYBN
Cybin Inc.
$8.28
Mkt Cap: $0.4B
LNSR
LENSAR, Inc.
$11.50
Mkt Cap: $0.1B
LUCD
Lucid Diagnostics Inc.
$1.18
Mkt Cap: $0.1B
MXCT
MaxCyte, Inc.
$1.33
Mkt Cap: $0.1B
NKTX
Nkarta, Inc.
$2.06
Mkt Cap: $0.1B
OWLT
Owlet, Inc.
$13.87
Mkt Cap: $0.2B
SAVA
Cassava Sciences, Inc.
$2.06
Mkt Cap: $0.1B
Explore stocks similar to AVR for comparison